These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26655262)

  • 21. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioligand Therapy With 177Lu-Prostate-Specific Membrane Antigen in a Patient With Non-Prostate-Specific Antigen-Secreting Metastatic Prostate Cancer.
    Pirayesh E
    Clin Nucl Med; 2020 Oct; 45(10):789-791. PubMed ID: 32701808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
    J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
    Pfestroff A; Luster M; Jilg CA; Olbert PJ; Ohlmann CH; Lassmann M; Maecke HR; Ezziddin S; Bodei L;
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1971-5. PubMed ID: 26373947
    [No Abstract]   [Full Text] [Related]  

  • 26. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs.
    de Blois E; Chan HS; de Zanger R; Konijnenberg M; Breeman WA
    Appl Radiat Isot; 2014 Feb; 85():28-33. PubMed ID: 24365877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-course
    Satapathy S; Das N; Sood A; Singh SK; Goyal S; Madan R; Mittal BR
    Eur Urol; 2021 Sep; 80(3):390-392. PubMed ID: 34175149
    [No Abstract]   [Full Text] [Related]  

  • 30. Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.
    Kletting P; Schuchardt C; Kulkarni HR; Shahinfar M; Singh A; Glatting G; Baum RP; Beer AJ
    PLoS One; 2016; 11(9):e0162303. PubMed ID: 27611841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
    Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
    Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
    Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S
    Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results: will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant prostate cancer in the coming years?
    Basu S; Parghane RV; Joshi A; Prabhash K; Banerjee S
    Nucl Med Commun; 2018 Dec; 39(12):1061-1063. PubMed ID: 30339554
    [No Abstract]   [Full Text] [Related]  

  • 37. What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
    Simone CB; Hahn SM
    Clin Cancer Res; 2013 Sep; 19(18):4908-10. PubMed ID: 23926229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of
    Azorín-Vega E; Aranda-Lara L; Torres-García E; Santiago-Bañuelos JA
    Appl Radiat Isot; 2019 Apr; 146():24-28. PubMed ID: 30743222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
    Ahmadzadehfar H; Albers P; Bockisch A; Boegemann M; Böhme C; Burchert W; Dietlein M; Drzezga A; Fabry U; Feldmann G; Heidenreich A; Heinzel A; Herrmann K; Heyll A; Höhling C; Kreuzer C; Laufer D; Mengel R; Mottaghy FM; Müller HW; Müller SC; Ost E; Rahbar K; Reifenhäuser W; Schäfers M; Schlenkhoff C; Schmidt M; Schmidt-Wolf I; Wildenhain C; Zimmer B; Essler M
    Urologe A; 2018 Jun; 57(6):709-713. PubMed ID: 29671080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a ¹⁷⁷Lu-labeled RGD derivative for targeting angiogenesis.
    Ju CH; Jeong JM; Lee YS; Kim YJ; Lee BC; Lee DS; Chung JK; Lee MC; Jeong SY
    Cancer Biother Radiopharm; 2010 Dec; 25(6):687-91. PubMed ID: 21204763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.